This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pamrevlumab
DrugBank Accession Number
DB14952
Background

Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Type
Biotech
Groups
Investigational
Synonyms
  • Pamrevlumab
External IDs
  • FG-3019

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Pamrevlumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pamrevlumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Pamrevlumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Pamrevlumab.
AmivantamabThe risk or severity of adverse effects can be increased when Pamrevlumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Pamrevlumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Pamrevlumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pamrevlumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pamrevlumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QS5F6VTS0O
CAS number
946415-13-0

References

General References
Not Available
Wikipedia
Pamrevlumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)2
3Active Not RecruitingTreatmentNonresectable Pancreatic Cancer1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
3RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Pancreatic Metastatic Cancer1
2Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
2TerminatedTreatmentCoronavirus Disease 2019 (COVID‑19)1
2TerminatedTreatmentDiabetic Kidney Disease (DKD) / Diabetic Nephropathy / Type 2 Diabetes Mellitus1
2TerminatedTreatmentLiver Fibrosis Due to Chronic Hepatitis B Infection1
2, 3CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia / COVID-19 Respiratory Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:37 / Updated at February 21, 2021 18:55